Scandion Oncology AS (OSTO:SCOL)
kr 0.0735 -0.0015 (-2%) Market Cap: 17.25 Mil Enterprise Value: -5.39 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 0/100

Q4 2021 Scandion Oncology A/S Earnings Call Transcript

Feb 17, 2022 / 07:30AM GMT
Release Date Price: kr4.28 (-0.14%)
Operator

Hello, and welcome to the Scandion Oncology audiocast with teleconference. With us today, we have CEO, Bo Rode Hansen, and CFO, Johnny Stilou. And for the first part of this call, all participants will be in a listen-only mode. And afterwards there will be a question-and-answer session. I will now hand over to the speakers. Please go ahead.

Bo Hansen;S;President
Scandion Oncology A;CEO & Director

/- -

Thank you and good morning, everyone. And thanks for listening in. Welcome to our Q4 2021 interim report investor call. As you just heard, my name is Bo Rode Hansen, and I'm the CEO and President of Scandion Oncology. With me today is also our CFO, Johnny Stilou, and we will be updating you on the development and financial results for the fourth quarter of 2021, as well as some recent events.

Overall, it was another productive quarter for Scandion, with good strategic progress as we moved our clinical and preclinical programs forward, and we remain on track for readouts from our two clinical trials later this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot